MetaCap

ADARx Pharmaceuticals (ADRX) vs Precigen (PGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precigen is the larger company by market cap ($1.51 billion vs $1.42 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADRX-33.90%PGEN-45.68%
+13%-18%-49%
Sep 25, 20261 yearNov 20, 2026
ADRX-33.90%PGEN-45.68%
+13%-18%-48%
Sep 21, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADRX versus PGEN key metrics
MetricADRXPGEN
Share price$12.79$4.21
Market cap$1.42B$1.51B
1-day change-9.68%+1.20%
YTD return—+0.72%
1-year return—+8.51%
5-year return—+9.07%
P/E ratio (TTM)—38.27
EPS (TTM)$-6.75$0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$9.68M
Revenue growth (YoY)—+146.73%
Net income (latest FY)—$-250.64M
Operating margin—-1141.13%
Net margin—-2588.21%
52-week high$23.21$8.98
52-week low$12.50$3.04
Distance from 52-week high-44.89%-53.12%
Analyst consensusstrong_buybuy
Avg. price target upside+167.79%+224.70%
Average volume650.63K5.68M
Shares outstanding111.19M358.55M
Employees100160
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ADARx Pharmaceuticals

ADRX stock →

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Precigen

PGEN stock →

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees

ADRX vs PGEN FAQ

Which is bigger, ADARx Pharmaceuticals or Precigen?

Precigen (PGEN) is larger, with a market capitalization of $1.51B compared with $1.42B for ADARx Pharmaceuticals (ADRX).

Are ADARx Pharmaceuticals and Precigen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons